BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31625710)

  • 1. Aspirin reduces the incidence of postmenopausal osteoporosis in rats through OPG-RANKL-RANK signaling pathway.
    Ma L; Liu X; Sun G
    Minerva Endocrinol; 2019 Dec; 44(4):408-410. PubMed ID: 31625710
    [No Abstract]   [Full Text] [Related]  

  • 2. Resveratrol restores the level of key inflammatory cytokines and RANKL/OPG ratio in the femur of rat osteoporosis model.
    Khera A; Kanta P; Kalra J; Dumir D; M T
    J Women Aging; 2019; 31(6):540-552. PubMed ID: 30239309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.
    He XF; Zhang L; Zhang CH; Zhao CR; Li H; Zhang LF; Tian GF; Guo MF; Dai Z; Sui FG
    Bosn J Basic Med Sci; 2017 Nov; 17(4):295-301. PubMed ID: 29055350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway.
    Zhao Y; Li J; Liu Y; Yu KQ; Zhang J; Chen XG
    J Pharm Pharmacol; 2007 Aug; 59(8):1167-73. PubMed ID: 17725861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
    Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
    Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Electroacupuncture Intervention Improves Cartilage Degeneration and Subchondral Bone Osteoporosis of Knee-joint Possibly by Adjusting OPG/RANK/RANKL Signaling in Ovariectomized Rats].
    Sun GH; Liao Y; Liao Y; Ni ZY; Li N; Zhong PR; Li XH; Zhou J
    Zhen Ci Yan Jiu; 2018 Dec; 43(12):781-7. PubMed ID: 30585456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M; Rieske P; Cegłowska A; Stêpień-Kłos W; Liberski PP; Brzeziańska E; Sewerynek E
    J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic supplement with melatonin successfully suppresses the pathogenesis of periodontitis through normalizing RANKL/OPG ratio and depressing the TLR4/MyD88 signaling pathway.
    Renn TY; Huang YK; Feng SW; Wang HW; Lee WF; Lin CT; Burnouf T; Chen LY; Kao PF; Chang HM
    J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29274168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR.
    Liu F; Tan F; Tong W; Fan Q; Ye S; Lu S; Teng Z; Han M; Zhang M; Chai Y
    Biomed Pharmacother; 2018 Jul; 103():1052-1060. PubMed ID: 29710663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RANKL/RANK/OPG signal trail: significance of genetic polymorphisms in the etiology of postmenopausal osteoporosis.
    Wolski H; Drews K; Bogacz A; Kamiński A; Barlik M; Bartkowiak-Wieczorek J; Klejewski A; Ożarowski M; Majchrzycki M; Seremak-Mrozikiewicz A
    Ginekol Pol; 2016; 87(5):347-52. PubMed ID: 27304650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-34a alleviates steroid-induced avascular necrosis of femoral head by targeting Tgif2 through OPG/RANK/RANKL signaling pathway.
    Peng WX; Ye C; Dong WT; Yang LL; Wang CQ; Wei ZA; Wu JH; Li Q; Deng J; Zhang J
    Exp Biol Med (Maywood); 2017 Jun; 242(12):1234-1243. PubMed ID: 28454497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK/RANKL/OPG system in the intervertebral disc.
    Takegami N; Akeda K; Yamada J; Sano T; Murata K; Huang J; Masuda K; Sudo A
    Arthritis Res Ther; 2017 Jun; 19(1):121. PubMed ID: 28576140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M; Sewerynek E; Król I; Stępień-Kłos W; Jędrzejczyk S
    Endokrynol Pol; 2016; 67(2):174-84. PubMed ID: 26884284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of combined salmon calcitonin and aspirin therapy for osteoporosis in ovariectomized rats.
    Wei J; Wang J; Gong Y; Zeng R
    Mol Med Rep; 2015 Aug; 12(2):1717-26. PubMed ID: 25891179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway.
    Mencej-Bedrač S; Zupan J; Mlakar SJ; Zavratnik A; Preželj J; Marc J
    Drug Metabol Drug Interact; 2014; 29(2):111-4. PubMed ID: 24615483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.